Edwards Lifesciences Corp (EW) Shares Sold by OLD Mutual Customised Solutions Proprietary Ltd.

OLD Mutual Customised Solutions Proprietary Ltd. lowered its stake in Edwards Lifesciences Corp (NYSE:EW) by 6.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,498 shares of the medical research company’s stock after selling 700 shares during the quarter. OLD Mutual Customised Solutions Proprietary Ltd.’s holdings in Edwards Lifesciences were worth $1,528,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of Edwards Lifesciences by 1.6% during the 1st quarter. BlackRock Inc. now owns 15,653,522 shares of the medical research company’s stock valued at $2,183,978,000 after buying an additional 242,785 shares in the last quarter. FMR LLC raised its position in shares of Edwards Lifesciences by 32.9% during the 2nd quarter. FMR LLC now owns 6,714,684 shares of the medical research company’s stock valued at $977,456,000 after buying an additional 1,663,511 shares in the last quarter. Brown Advisory Inc. raised its position in shares of Edwards Lifesciences by 5.8% during the 2nd quarter. Brown Advisory Inc. now owns 3,866,016 shares of the medical research company’s stock valued at $562,775,000 after buying an additional 211,258 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Edwards Lifesciences by 5.3% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,147,510 shares of the medical research company’s stock valued at $312,614,000 after buying an additional 107,676 shares in the last quarter. Finally, Royal Bank of Canada raised its position in shares of Edwards Lifesciences by 9.1% during the 1st quarter. Royal Bank of Canada now owns 1,550,377 shares of the medical research company’s stock valued at $216,309,000 after buying an additional 129,036 shares in the last quarter. Institutional investors and hedge funds own 82.11% of the company’s stock.

Edwards Lifesciences stock opened at $147.99 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.47 and a current ratio of 1.86. Edwards Lifesciences Corp has a 1-year low of $100.20 and a 1-year high of $156.87. The stock has a market capitalization of $30.34 billion, a P/E ratio of 38.94, a PEG ratio of 2.00 and a beta of 0.57.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 26th. The medical research company reported $1.24 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.13 by $0.11. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The company had revenue of $972.00 million for the quarter, compared to analyst estimates of $968.32 million. During the same period in the prior year, the company posted $1.08 EPS. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. sell-side analysts expect that Edwards Lifesciences Corp will post 4.67 EPS for the current fiscal year.

Several brokerages have recently issued reports on EW. ValuEngine cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, June 6th. Zacks Investment Research upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Saturday, July 14th. BMO Capital Markets upped their target price on shares of Edwards Lifesciences to $162.00 and gave the company an “outperform” rating in a research report on Tuesday, July 10th. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $138.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday, July 27th. Finally, Sanford C. Bernstein began coverage on shares of Edwards Lifesciences in a research report on Wednesday, June 27th. They set a “market perform” rating and a $165.00 target price on the stock. One analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $152.45.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction dated Tuesday, July 31st. The shares were sold at an average price of $141.86, for a total value of $4,667,194.00. Following the transaction, the chief executive officer now directly owns 43,126 shares in the company, valued at approximately $6,117,854.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Huimin Wang sold 3,800 shares of the company’s stock in a transaction dated Thursday, July 5th. The stock was sold at an average price of $146.60, for a total transaction of $557,080.00. The disclosure for this sale can be found here. Insiders sold a total of 177,511 shares of company stock worth $25,420,691 over the last three months. 1.84% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

See Also: Penny Stocks, What You Need To Know

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply